BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Shionogi brings treatment for Gram-Negative Bacterial Infections in Singapore and Malaysia

November 16, 2026 | News

Link will obtain exclusive rights to develop and launch cefiderocol in Singapore and Malaysia



Japan-based pharma firm Shionogi has entered into a license agreement with Link Healthcare, headquartered in Singapore, for the development and market development of cefiderocol, a treatment for Gram-negative bacterial infections discovered by Shionogi, in Singapore and Malaysia.

In March 2025, Shionogi entered into a license agreement with Link Medical Products Pty Ltd, which, like Link, is part of Clinigen, for the development and market development of cefiderocol in Australia and New Zealand, and the companies have since been collaborating to make cefiderocol available in these markets. Through this new Agreement, Shionogi is expanding its collaboration with Clinigen to Singapore and Malaysia, with the aim of making cefiderocol available to patients in both countries as a new treatment option, while promoting the appropriate use of antibiotics.

Under the terms of the Agreement, Link will obtain exclusive rights to develop and launch cefiderocol in Singapore and Malaysia. Link will be responsible for regulatory submissions, obtaining marketing approvals, and in-market activities in both countries. Under the terms of the Agreement, Shionogi will receive payments from Link in connection with the development and supply of cefiderocol.

Cefiderocol is an antibiotic that effectively penetrates the outer membrane of Gram-negative bacteria, including multidrug-resistant strains, and exerts antibacterial activity. Cefiderocol is commercially available in multiple countries and regions, including Japan, the United States, Europe, Taiwan, and South Korea. Cefiderocol is included in the WHO Model List of Essential Medicines and plays an important role globally as a treatment option for infections caused by antimicrobial-resistant bacteria.